Atlas Trials

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Clinical trial NCT05106309 · COMPLETED

Trial details

NCT number
NCT05106309
Sponsor
Cerevel Therapeutics, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2021-12-29
Primary completion
2022-02-24
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.